A phase II feasibility study of cytarabine and idarubicin combination in relapsed or refractory adult acute lymphoblastic leukemia

被引：0
|
作者：
Hafeez, M. [1 ]
Shaharyar, A. [1 ]
Zia, N. [1 ]
Rasheed, H. [1 ]
机构：
[1] King Edward Med Univ, Mayo Hosp, Lahore, Pakistan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18002
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II Study of the Combination of Clofarabine Plus Idarubicin and Cytarabine (CIA) In Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
    Naqvi, Kiran
    Ravandi, Farhad
    Kantarjian, Hagop
    Borthakur, Gautam
    Ferrajoli, Alessandra
    Thomas, Deborah A.
    Koller, Charles Asa
    Konopleva, Marina
    Byrd, Anna
    Kwari, Monica
    Faderl, Stefan
    BLOOD, 2010, 116 (21) : 464 - 465
  • [2] Phase II dosing study of cytarabine chemotherapy in combination with cenersen (EL625) and idarubicin in refractory and relapsed acute myelogenous leukemia (AML)
    Alvarado, Y.
    Kantarjian, H.
    Freireich, E. J.
    Garcia-Manero, G.
    Ferrajoli, A.
    Koller, C.
    Estrov, Z.
    Kornblau, S.
    Laddie, N.
    Smith, L.
    Cortes, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] IDARUBICIN AND HIGH-DOSE CYTARABINE IN THE TREATMENT OF REFRACTORY AND RELAPSED ACUTE LYMPHOBLASTIC-LEUKEMIA
    GIONA, F
    TESTI, AM
    AMADORI, S
    MELONI, G
    CAROTENUTO, M
    RESEGOTTI, L
    COLELLA, R
    LEONI, P
    CARELLA, AM
    GROTTO, P
    MINIERO, R
    MANDELLI, F
    ANNALS OF ONCOLOGY, 1990, 1 (01) : 51 - 55
  • [4] VM-26 AND CYTARABINE COMBINATION CHEMOTHERAPY IN REFRACTORY OR RELAPSED ADULT ACUTE LYMPHOBLASTIC-LEUKEMIA
    CARELLA, AM
    SANTINI, G
    MARTINENGO, M
    GIORDANO, D
    NATI, S
    CONGIU, A
    RISSO, M
    VIMERCATI, R
    CERRI, R
    ROSSI, E
    DAMASIO, E
    MARMONT, AM
    HAEMATOLOGICA, 1984, 69 (06) : 747 - 751
  • [5] IDARUBICIN IN COMBINATION WITH ETOPOSIDE AND CYTARABINE IN ADULT UNTREATED ACUTE NON LYMPHOBLASTIC-LEUKEMIA
    CARELLA, AM
    MARTINENGO, M
    SANTINI, G
    GAOZZA, E
    DAMASIO, E
    GIORDANO, D
    NATI, S
    CONGIU, A
    CERRI, R
    RISSO, M
    GANZINA, F
    MARMONT, AM
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1987, 23 (11): : 1673 - 1678
  • [6] IDARUBICIN IN COMBINATION WITH ETOPOSIDE AND CYTARABINE IN ADULT ACUTE NON-LYMPHOBLASTIC LEUKEMIA (ANLL)
    CARELLA, AM
    PUNGOLINO, E
    PIATTI, G
    GIORDANO, D
    CERRI, R
    RISSO, M
    NATI, S
    BONE MARROW TRANSPLANTATION, 1989, 4 : 50 - 51
  • [7] A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia
    Fiedler, Walter
    Chromik, Joerg
    Amberg, Stefanie
    Kebenko, Maxim
    Thol, Felicitas
    Schlipfenbacher, Vera
    Christine Wilke, Anne
    Modemann, Franziska
    Janning, Melanie
    Serve, Hubert
    Ganser, Arnold
    Bokemeyer, Carsten
    Theile, Susann
    Deppermann, Ute
    Kranich, Anne L.
    Heuser, Michael
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 190 (03) : E169 - E173
  • [8] SWOG S0919: A phase II study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukemia (AML)
    Advani, Anjali S.
    McDonough, Shannon
    Copelan, Edward
    Willman, Cheryl L.
    Mulford, Deborah A.
    List, Alan F.
    Sekeres, Mikkael A.
    Othus, Megan
    Erba, Harry P.
    Appelbaum, Frederick R.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [9] Phase II study of liposomal vincristine (lipoV) in relapsed or refractory adult acute lymphoblastic leukemia (ALL).
    Thomas, DA
    Sarris, A
    O'Brien, S
    Cortes, J
    Giles, FJ
    Faderl, S
    Keating, MJ
    Burge, C
    Cabanillas, F
    Kantarjian, H
    BLOOD, 1999, 94 (10) : 238B - 238B
  • [10] Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory acute lymphoblastic leukemia in adults. A phase II study by the Polish Adult Leukemia Group (PALG)
    Giebel, S
    Krawczyk-Kulis, M
    Jakubas, B
    Adamczyk-Cioch, M
    Palynyczko, G
    Holowiecki, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 613S - 613S
12345